534,078 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Leigh Baldwin & CO. LLC

Leigh Baldwin & CO. LLC bought a new position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 534,078 shares of the biopharmaceutical company's stock, valued at approximately $30,207,000.

A number of other large investors have also recently made changes to their positions in the business. Norges Bank bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $1,989,525,000. Ameriprise Financial Inc. boosted its position in Bristol-Myers Squibb by 59.9% during the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after purchasing an additional 12,011,983 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Bristol-Myers Squibb by 701.2% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after purchasing an additional 10,913,708 shares during the period. Wellington Management Group LLP increased its stake in shares of Bristol-Myers Squibb by 3,880.0% in the fourth quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock worth $338,088,000 after purchasing an additional 5,827,317 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $257,618,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Up 3.6%

NYSE:BMY traded up $1.60 during midday trading on Thursday, reaching $45.72. 27,423,080 shares of the stock traded hands, compared to its average volume of 13,257,092. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The business has a 50-day moving average of $53.69 and a two-hundred day moving average of $56.06. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market capitalization of $93.04 billion, a PE ratio of -10.34, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the company earned ($4.40) EPS. Bristol-Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. On average, equities analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were given a $0.62 dividend. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.42%. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Analysts Set New Price Targets

Several brokerages have commented on BMY. UBS Group cut their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Finally, Jefferies Financial Group decreased their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Bristol-Myers Squibb presently has a consensus rating of "Hold" and an average price target of $58.00.

Insider Activity

In other news, EVP Samit Hirawat acquired 1,823 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.09% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.